Action Duchenne leads the way
Action Duchenne continues to be at the forefront of UK research to find a cure and treatments for Duchenne.
Since 2001 as PPUK and now Action Duchenne we have led the way in new Duchenne Research. PPUK has funded 6 major projects for £350,000 and led the development of the £2.2m MDEX exon skipping project. Action Duchenne has recently established the ZF Partnership with drug discovery company Summit:
- 2003 Dr Qi Lu Imperial College London Systemic delivery of Antisense oligoribonucleotide
- 2003 Professor Kate Bushby and Dr Michelle Eagle Use of steroids for non ambulatory boys with DMD Newcastle University
- 2003 Establishing the MDEX consortium with leading UK scientists and Clinicians in partnership with the Muscular Dystrophy Campaign and Duchenne Family Support Group
- 2004 Funding of £2m for the MDEX consortium from the Department of Health and the Medical Research Council
- 2005 Dr Jenny Morgan and Professor Francesco Muntoni Imperial College London Stem cell therapy using a lentivirus to modify the faulty gene
- 2006 Professor Kay Davies University of Oxford Using AAV/U7 to develop exon skipping for Duchenne
- 2006 Professor Steve Wilton University of Western Australia Using explants to develop Exon skipping
- 2007 £1m ZF Partnership project with UK biotech company Summit to discover new drugs for Duchenne and to support their utrophin upregulation drug programme
Funding Partners
Association Monegasque contre less Myopathies
Parent Project France
Gavriel Meir Trust
Charleys Fund